Specialty Pharmaceutical Supply (High-Cost/Therapeutic Class-Specific)

The contract pertains to the supply of high-cost specialty pharmaceuticals, including treatments for Hepatitis D, oncology therapies, and biologics, with pricing determined through Average Domestic Price mechanisms and robust utilization management protocols such as prior authorization requirements. These drugs are critical for specialized patient populations and require strict control over dispensing to ensure appropriate use, cost transparency, and regulatory compliance. The award will be structured as a subcontract under the Defense Health Agency’s broader procurement framework, with performance expectations centered on reliable, compliant distribution and ongoing support for clinical and administrative oversight. The solicitation was posted on July 9, 2026, with responses due by July 27, 2026, and falls under NAICS code 325412, which classifies pharmaceutical and medicine manufacturing. The place of performance is designated with a ZIP code of 78230, indicating the primary logistics or fulfillment hub is located in San Antonio, Texas. This contract is part of the Department of Defense’s effort to secure access to advanced, often life-saving medications for military and eligible dependent populations, emphasizing affordability, traceability, and adherence to federal pharmaceutical procurement standards. No set-aside provisions are specified, and the contract is open to qualified subcontractors meeting technical, regulatory, and supply chain requirements.